The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio’s PRV; RMAT Designation For PolarityTE’s Product
Here's a roundup of top developments in the biotech space over the last 24 hours:
Editas Medicine Reports Received FDA Orphan Drug Designation For EDIT-301 For Treatment Of Beta Thalassemia
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational, gene editing
Expert Ratings for Editas Medicine
Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter:
Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $15
Morgan Stanley maintains Editas Medicine (NASDAQ:EDIT) with a Underweight and lowers the price target from $17 to $15.
Editas Medicine Q1 EPS $(0.74) Beats $(0.79) Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.79) by 6.33 percent. This is a 13.95 percent increase over losses of $(0.86) per share from
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Editas Medicine Earnings Conference Call Is Coming Up, Here’s What You Need To Know
Editas Medicine (NASDAQ:EDIT) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
How to Attend Editas Medicine (EDIT) Conference Call
Follow this link to access the live webcast.
Editas Medicine Announces Dosing Of First Pediatric Patient In BRILLIANCE Clinical Trial Of EDIT-101 For LCA10
Marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient
Company on track to complete dosing of the pediatric mid-dose cohort in the first half of 2022 and expects to
Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad’s CRISPR Patents
The U.S. Patent and Trademark Office has ruled in favor of the Broad Institute of MIT and Harvard…